Thakkar Roopal 4

What Happened

• Roopal Thakkar, Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie, was reported as acquiring a total of 40,074 equity awards on Feb 18, 2026. The filing shows four awards of common stock/RSUs (6,015; 2,138; 3,346; 6,638 shares) and a derivative award of 21,937 (employee stock option). Each line is reported as an acquisition at $0.00 (awards/grants), so no cash was paid at grant. The performance-vesting restrictions for the RSU/performance share awards were certified as satisfied and released; those shares will be issued to Thakkar on February 28, 2026. The option award vests in annual increments beginning Feb 18, 2027 (7,313; 7,312; 7,312).

Key Details

• Transaction date: February 18, 2026; Report filed: February 20, 2026 (timely).
• Transaction type: A = Award/Grant; reported acquisition price $0.00; total shares awarded = 40,074.
• Issuance/vesting: RSU/performance shares to be issued Feb 28, 2026 after Compensation Committee certification; option vests in annual increments on 2/18/2027, 2/18/2028 and 2/18/2029.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Notable footnotes: Awards are performance-vesting and were released upon certification of performance goals (see F1–F4). The derivative entry (F5) is an employee stock option granted under AbbVie’s 2013 Incentive Stock Program and is exempt under Rule 16b‑3.
• Filing timeliness: No late filing indicated.

Context

• These were performance-based awards and an option grant, not open-market purchases or sales. The RSUs/performance shares were released after certification of goals and will be issued on Feb 28, 2026; the option grant vests over the next three years. Awards paid as compensation are common for executives and do not by themselves indicate a buy/sell signal.